Servier licenses osteoporosis compound from Osteologix
This article was originally published in Scrip
Executive Summary
Osteologix, a US speciality pharma company focused on diseases of the bone and joints, has granted Servier Research Group of France an exclusive royalty-bearing licence to its lead product candidate, NB S101 (strontium malonate).